Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
Authors:
Open Access
- 29 June 2023
- journal article
- research article
- Published by Springer Nature in BMC Health Services Research
- Vol. 23 (1) , 1-10
Abstract
Background: The effectiveness of sacituzumab govitecan for metastatic triple-negative breast cancer (TNBC) has been reported in recent research, however, the value of the effectiveness and cost of sacituzumab govitecan is still unclear.Methods: A microsimulation model was developed using data from the ASCENT trial to assess the cost-effectiveness of sacituzumab govitecan for patients with relapsed or refractory metastatic TNBC over a lifetime. Model inputs, including clinical data, patient characteristics, and direct medical costs, were based on the ASCENT trial, public databases, and published literature. The primary outcomes of the model were the incremental cost-effectiveness ratio (ICER) and quality-adjusted life-years (QALYs). Univariate and probabilistic sensitivity analysis (PSA) and multiple scenario analyses were performed to address the uncertainty of the model.Results: Our results revealed that sacituzumab govitecan versus chemotherapy costs $293,037 and yielded an additional 0.2340 of QALYs in the whole population with metastatic TNBC, leading to an ICER of $1,252,295 gained. And in the population with metastatic TNBC without brain metastasis, the sacituzumab govitecan versus chemotherapy costs $309,949 and obtained an extra 0.2633 of QALYs, which resulted in an ICER of $1,177,171/QALYs. Univariate analyses indicated that the model outcomes were most sensitive to the drug cost of sacituzumab govitecan, the utility of progression-free disease, and the utility of progressed disease.Conclusion: From the US payer perspective, sacituzumab govitecan is unlikely to be a cost-effective option for patients with relapsed or refractory metastatic TNBC compared with chemotherapy. Based on the value standpoint, a price decrease of sacituzumab govitecan is expected to increase the cost-effectiveness of sacituzumab govitecan in patients with metastatic TNBC.Keywords
Funding Information
- Postgraduate Scientific Research Innovation Project of Hunan Province, China (CX20210350)
- Health and Family Planning Commission of Hunan Province (20200022)
This publication has 30 references indexed in Scilit:
- Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapyAnnals of Oncology, 2016
- Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2016
- A Review of Systemic Treatment in Metastatic Triple-Negative Breast CancerBreast Cancer: Basic and Clinical Research, 2016
- An overview of triple-negative breast cancerArchives of Gynecology and Obstetrics, 2015
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY ThresholdNew England Journal of Medicine, 2014
- Investigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World SettingThe Oncologist, 2014
- Comparing Local and Regional Variation in Health Care SpendingNew England Journal of Medicine, 2012
- Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trialBreast Cancer Research and Treatment, 2012
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Medical Research Methodology, 2012
- Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancerBreast Cancer Research and Treatment, 2010